Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease

Current Opinion in Pulmonary Medicine

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Coghlan, J Gerry ^a   Pope, Janet ^b   Denton, Christopher P ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Connective tissue disease; Pulmonary arterial hypertension; Time to clinical worsening

Indexed keywords

AMBRISENTAN; BOSENTAN; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST;

ASPIRATION; CLINICAL TRIAL; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FIBROSING ALVEOLITIS; HUMAN; MAJOR CLINICAL STUDY; MIXED CONNECTIVE TISSUE DISEASE; MORTALITY; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

COMORBIDITY; CONNECTIVE TISSUE DISEASES; ENDPOINT DETERMINATION; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; TIME FACTORS;

EID: 77951059060     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000370208.45756.e8     Document Type: Review

References (35)

1. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088-1093.
2. Shen JY, Chen SL, Wu YX, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999; 18:147-151.
3. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000; 9:338-342.
4. Denton CP, Nihtyanova SI. Therapy of pulmonary arterial hypertension in systemic sclerosis: an update. Curr Rheumatol Rep 2007; 9:158-164.
5. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151-157.
6. Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61:227-237. (Pubitemid 38091763)
7. WilliamsMH,Das C,HandlerCE, et al.Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92:926-932.
8. Ito T, Ozawa K, Shimada K. Current drug targets and future therapy of pulmonary arterial hypertension. Curr Med Chem 2007; 14:719-733.
9. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease.Arandomized, controlled trial.Ann InternMed2000; 132:425-434.
10. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329. (Pubitemid 34815354)
11. Simonneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-804.
12. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126:420-427.
13. Galiè N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39:1496-1502.
14. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:2119-2125. (Pubitemid 36724255)
15. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-1123. (Pubitemid 32971843)
16. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
17. Galiè N, Hoeper MM, Jansa P, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371:2093-2100.
18. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65:1336-1340.
19. Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008; 67:1222-1228.
20. Pope JE, Gabrielli A, Peter H, et al. Long-term effects of bosentan treatment on survival in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD). Arthritis Rheum 2007; 56 (9 Suppl):1199.
21. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169:441-447.
22. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47:2049-2056.
23. Girgis RE, Frost AE, Hill NS, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007; 66:1467-1472.
24. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010-3019.
25. Badesch D, on behalf of the ARIES study group. Ambrisentan therapy for pulmonary arterial hypertension: a comparison by PAH etiology. Chest 2007; 132:488S.
26. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157. (Pubitemid 41653106)
27. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894-2903.
28. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515-522.
29. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149:521-530.
30. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26:858-863.
31. McLaughlin V, Rubin L, Benza R, et al. TRIUMPH I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2008; 177 (Abstracts Issue):A965.
32. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174:1257-1263.
33. Badesch D, Burgess G, Parpia T, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007; 34:2417-2422.
34. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.
35. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart 2008; 94 (Suppl 1):i1-i41.